The IND clearance removes a key regulatory obstacle for U.S. trial expansion, de-risking the program for Accelerated Approval. Monitor enrollment updates and interim data from THIO-101 Parts C/D, as positive results could significantly impact valuation given the small market cap.
Price Chart
Executive Summary
MAIA Biotechnology announced FDA clearance of an IND amendment to open U.S. enrollment for the expansion of its Phase 2 THIO-101 trial of ateganosine in third-line NSCLC. This regulatory green light, combined with prior Fast Track designation, supports potential Accelerated Approval filing. The company plans up to five U.S. clinical sites, with initial site already active.
Key Facts
- FDA cleared IND amendment allowing U.S. enrollment for Phase 2 THIO-101 expansion in third-line NSCLC.
- First U.S. clinical site activated at Summit Medical Group in New Jersey; up to five sites planned in 2026.
- Fast Track designation granted July 2025 enables rolling review and potential Accelerated Approval.
- Phase 3 trial THIO-104 (pivotal) is actively screening patients for ateganosine plus CPI vs. chemotherapy.
- Data from THIO-101 Parts A/B showed overall survival beyond two years for eight patients.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $82M market cap.
Risk Factors
- Phase 2/3 data may fail to meet endpoints, leading to clinical hold or approval denial.
- Financing risk: company may need to raise capital to fund expanded U.S. trial and Phase 3.
- Competition from approved NSCLC therapies (e.g., Keytruda, Opdivo) may limit commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Oct 6, 2026 21d ago | 8-K | $1.19 | awaiting T+60 | — | $1.11 (−6.72%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.11 (−20.71%) |
Sep 15, 2026 6w ago | Press Release | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Sep 15, 2026 6w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.11 (−22.38%) |
Jun 2, 2026 21w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.11 (−17.78%) |
May 19, 2026 23w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.11 (−9.76%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.11 (−11.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers